单位:[1]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China华中科技大学同济医学院附属同济医院[2]Institute of Organ Transplantation,Key Laboratory of the National Health Commission,the Ministry of Education and Chinese Academy of Medical Sciences,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China器官移植研究所华中科技大学同济医学院附属同济医院器官移植
ObjectiveWe aimed to identify new, more accurate risk factors of liver transplantation for liver cancer through using the Surveillance, Epidemiology, and End Results (SEER) database.MethodsUsing the SEER database, we identified patients that had undergone surgical resection for non-metastatic hepatocellular carcinoma (HCC) and subsequent liver transplantation between 2010 and 2017. Overall survival (OS) was estimated using Kaplan-Meier plotter. Cox proportional hazards regression modelling was used to identify factors independently associated with recurrent disease [presented as adjusted hazard ratios (HR) with 95% CIs].ResultsTotally, 1530 eligible patients were included in the analysis. There were significant differences in ethnicity (P=0.04), cancer stage (P<0.001), vascular invasion (P<0.001) and gall bladder involvement (P<0.001) between the groups that survived, died due to cancer, or died due to other causes. In the Cox regression model, there were no significant differences in OS at 5 years with different operative strategies (autotransplantation versus allotransplantation), nor at survival at 1 year with neoadjuvant radiotherapy. However, neoadjuvant radiotherapy did appear to improve survival at both 3 years (HR: 0.540, 95% CI: 0.326-0.896, P=0.017) and 5 years (HR: 0.338, 95% CI: 0.153-0.747, P=0.007) from diagnosis.ConclusionThis study demonstrated differences in patient characteristics between prognostic groups after liver resection and transplantation for HCC. These criteria can be used to inform patient selection and consent in this setting. Preoperative radiotherapy may improve long-term survival post-transplantation.
基金:
National Natural Science Foundation of China [82000602]; Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province [CXPJJH11900001-2019330]; Innovation Team Project of Health Commission of Hubei Province [WJ2021C001]
第一作者单位:[1]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China[2]Institute of Organ Transplantation,Key Laboratory of the National Health Commission,the Ministry of Education and Chinese Academy of Medical Sciences,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
共同第一作者:
通讯作者:
通讯机构:[1]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China[2]Institute of Organ Transplantation,Key Laboratory of the National Health Commission,the Ministry of Education and Chinese Academy of Medical Sciences,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
推荐引用方式(GB/T 7714):
Li Jun-bo,Zhao Yuan-yuan,Dai Chen,et al.Prognostic Factors of Liver Transplantation for Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis[J].CURRENT MEDICAL SCIENCE.2023,43(2):329-335.doi:10.1007/s11596-023-2720-y.
APA:
Li, Jun-bo,Zhao, Yuan-yuan,Dai, Chen,Chen, Dong,Wei, Lai...&Chen, Zhi-shui.(2023).Prognostic Factors of Liver Transplantation for Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.CURRENT MEDICAL SCIENCE,43,(2)
MLA:
Li, Jun-bo,et al."Prognostic Factors of Liver Transplantation for Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis".CURRENT MEDICAL SCIENCE 43..2(2023):329-335